Enterococcus Specific Neutra™ Antibody Products
Product listStruggling with multidrug-resistant Enterococcus infections or unreliable antibody performance? Creative Biolabs' Enterococcus specific Neutra™ antibody products overcome antimicrobial resistance challenges using high-precision epitope mapping and validated neutralizing activity, accelerating therapeutic development and improving diagnostic accuracy.
Introduction to Enterococcus
Enterococcus, a Gram-positive facultative anacrobe, resides commensally in human and animal gastrointestinal tracts but acts as an opportunistic pathogen. Notable species like Enterococcus faecalis and E. faecium are leading causes of hospital-acquired infections, particularly vancomycin-resistant enterococci (VRE), which exhibit alarming resistance to first-line therapies. Their resilience stems from intrinsic antibiotic tolerance and horizontal gene transfer mechanisms, complicating treatment protocols globally.
- Structural Insights
The Enterococcus cell wall features the peptidoglycan layers interspersed with lipoteichoic acids and surface adhesins (e.g., Esp, Ace), critical for biofilm formation and host cell adherence. These structural components also serve as prime targets for neutralizing antibodies. Recent studies highlight the role of polysaccharide capsules in immune evasion, while pilus-like structures facilitate colonization and virulence.
- Resistance and Signaling Pathways
Enterococci deploy sophisticated resistance mechanisms, including:
- Vancomycin Resistance: Mediated by vanA or vanB gene clusters altering cell wall precursors.
- β-lactamase Production: Hydrolyzes penicillin derivatives, often encoded on mobile genetic elements.
- Efflux Pumps: Expel fluoroquinolones and tetracyclines.
These pathways intersect with host immune responses, such as TLR2/NF-κB activation, triggering inflammation while enabling bacterial persistence.
Fig.1 Summary of the principal mechanism of enterococcal antibiotic resistance.1
- Clinical Impact
Enterococcus causes life-threatening conditions:
- Urinary tract infections (UTIs): Common in catheterized patients.
- Bacteremia and endocarditis: High mortality rates in immunocompromised populations.
- Surgical site infections: Linked to biofilm formation on medical devices.
VRE outbreaks in healthcare settings underscore the urgency for targeted interventions.
Applications of Anti-Enterococcus Neutralizing Antibodies
- Diagnostic Development
Rapid detection of VRE strains using antibody-based assays reduces diagnostic delays. For instance, monoclonal antibodies against VanA or VanB phenotypes differentiate resistant isolates within 2 hours, guiding timely antibiotic stewardship.
- Therapeutic Intervention
Neutralizing antibodies synergize with antibiotics to enhance efficacy. In murine models, anti-Esp mAbs reduced bacterial load in endocarditis by 80%, while anti-biofilm antibodies restored susceptibility to vancomycin in chronic UTIs.
- Prophylaxis in High-Risk Settings
Administration of anti-adhesin antibodies preoperatively prevents device-associated infections. A Phase II trial demonstrated a 60% reduction in surgical site infections among colorectal surgery patients receiving antibody prophylaxis.
- Monitoring Treatment Response
Quantifying antibody titers post-therapy predicts clinical outcomes. Persistent anti-Enterococcus IgG levels correlate with reduced relapse rates in bacteremia cases.
Our Anti-Enterococcus Neutralizing Antibodies
Creative Biolabs' antibodies target virulence determinants and resistance factors:
- Anti-lipoteichoic acid antibodies: Disrupt biofilm integrity and bacterial adherence.
- Anti-Esp monoclonal antibodies (mAbs): Block colonization in preclinical models.
- Vancomycin-resistance biomarkers: Enable rapid VRE strain identification.
Validated for specificity (>95% binding affinity) and reproducibility across ELISA, flow cytometry, and immunofluorescence, these tools empower researchers to decode resistance mechanisms and design precision therapies.
Creative Biolabs delivers rigorously validated Enterococcus specific Neutra™ antibodies to combat antimicrobial resistance and streamline therapeutic innovation. Contact our scientific team today to discuss custom solutions tailored to your specific research needs.
REFERENCE
- Sangiorgio, Giuseppe, et al. "The impact of Enterococcus spp. in the immunocompromised host: a comprehensive review." Pathogens 13.5 (2024): 409. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3390/pathogens13050409
